Health Canada has issued an alert after Gore identified, through quality‑control testing, that a subset of its VIABAHN® endoprosthesis devices were processed using equipment that was operating outside the validated range. This condition could potentially lead to an incorrect bonding location of the distal tip onto the delivery catheter.
Manufacturers and users are advised to review the affected product batches and follow any further guidance from Health Canada regarding corrective actions or product handling.
Actualizaciones regulatorias4 sept 2026•1 min de lectura
Gore VIABAHN® Device Quality Issue Identified
Gore discovered some VIABAHN® devices were processed on equipment outside validated range, risking incorrect distal tip bonding.
Recopilado por el equipo de PharmaCountry · Fuente: Health Canada
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración